Overview
On 9 January 2020, orphan designation EU/3/19/2239 was granted by the European Commission to Advicenne S.A, France, for tripotassium citrate monohydrate and potassium hydrogen carbonate (also known as ADV7103) for the treatment of cystinuria.
The sponsor’s address was updated in March 2021.
Key facts
Active substance |
|
Intended use |
Treatment of cystinuria
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/19/2239
|
Date of designation |
09/01/2020
|
Sponsor |
Advicenne S.A. |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: